Faculty/Presenter Disclosure

Size: px
Start display at page:

Download "Faculty/Presenter Disclosure"

Transcription

1 Faculty/Presenter Disclosure Faculty: Andre Lamy Relationships with commercial interests: Grants/Research Support: None Speakers Bureau/Honoraria: None Consulting Fees: None Other: None

2 CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University Hamilton, CANADA on behalf of the CORONARY Investigators

3 Disclosure No conflict of interest for all co-authors Presented on behalf of the CORONARY Investigators 3

4 Background Benefits and risks of performing CABG surgery on beating heart (off pump) not clearly established. Majority of prior trials had few events and short follow-up or inexperienced surgeons. 4

5 CORONARY Trial Organization 79 centers in 19 countries 4,752 patients recruited between (November 2006 October 2011) Designed, coordinated, managed and data analysed and reported by the Population Health Research Institute, Hamilton Health Sciences and McMaster University in Hamilton, Canada The data was monitored by independent DSMB Funded by Canadian Institutes of Health Research 5

6 Study Hypotheses - Off pump CABG compared to on-pump CABG would reduce major clinical events in shortterm (30 Days) - Benefits maintained in long-term (5 yrs) 6

7 Inclusion/Exclusion Criteria Inclusion Criteria Isolated CABG with median sternotomy One of the following: 1. Peripheral vascular disease 2. Cerebrovascular disease 3. Renal Insufficiency 4. Age 70 years 5. Age with at least one risk factor (diabetes, urgent revascularization, smoker, LVEF 35) 6. Age with at least two of the above risk factors Exclusions Additional cardiac procedure planned Contraindications to off-pump or on-pump CABG Emergency or re-do CABG 7

8 Qualifications of Surgeons Surgical expertise-based randomization > 2 years of experience as staff cardiac surgeon and > 100 cases of one or both techniques Trainees were not allowed to be primary operators 8

9 Primary Outcomes 1 st Co-Primary Outcome Composite of total mortality, stroke, non fatal myocardial infarction, new renal failure at 30 days post randomization NEJM NEJM 30 days: presented ACC.12 and 1 Year: presented ACC.13 and 2 nd Co-Primary Outcome Composite of above outcomes plus repeat coronary revascularization over 5 yrs of follow-up (expected 9

10 Baseline Characteristics OFF-PUMP (n = 2375) ON-PUMP (n = 2377) Mean Age (years) Males () Prior MI Previous Stroke Peripheral Arterial Disease Congestive Heart Failure Urgent Surgery Euroscore >

11 Baseline Disease Pre-op Angiogram OFF-PUMP (n = 2375) ON-PUMP (n = 2377) Left Main Triple Vessel Double Vessel Single Vessel

12 Operation Details 4752 Randomized (ITT Analyses) CABG 30 days Off Pump 2148 (90.4) On Pump 2183(91.8 ) Cross-overs 184 (7.8) 150 (6.4) Incomplete revascularization Operating room (median hrs) Initial ventilation (median hrs) Off Pump On Pump RR 95 CI p value < <

13 Conduits OFF-PUMP (n = 2375) ON-PUMP (n = 2377) p-value n n CABG Completed Total grafts performed CONDUIT <0.001 LIMA or RIMA Saphenous Vein <

14 Peri-operative Transfusions and Bleeding OFF-PUMP (n = 2375) ON-PUMP (n = 2377) p value Any Blood Transfusion <0.001 Antifibrinolytics <0.001 Re-operation for bleeding

15 1 st Co-Primary Outcome (30 Days) Primary Outcome Death, Stroke, MI, Renal Failure Off Pump On Pump Hazard Ratio 95 CI p value

16 1 st Co-Primary Outcome (30 Days) Primary Outcome Death, Stroke, MI, Renal Failure Components Off Pump On Pump Hazard Ratio 95 CI p value Death Stroke Non Fatal MI New Renal Failure

17 Death/MI/Stroke/New Renal Failure at 30 Days Cumulative Event Rate # at Risk OFF ON HR CI p value 0.59 Off Pump On Pump 0 10 Days of Follow-up

18 Other Outcomes at 30 days Off Pump On Pump Hazard Ratio 95 CI p value Angina PCI Re-do CABG PCI/Re-do CABG All re-operations (re-do CABG) All re-operations/re-do CABG/PCI

19 Other Outcomes at 30 days Off Pump On Pump Relative Risk 95 CI p value Respiratory Infection or failure Acute Kidney Injury AKIN Stage RIFLE risk New Renal Failure requiring Dialysis Acute Kidney Injury Network (AKIN): absolute increase in serum creatinine value 27 µmol/l OR an increase of 150 from the baseline serum creatinine value Risk, Injury, Failure, Loss and End-stage Renal Disease (RIFLE): increase of 150 from the baseline serum creatinine value 19

20 Primary Outcome at Hospital Discharge Tertiary Outcome Death/MI/Stroke/Renal Failure Off Pump On Pump Hazar d Ratio 95 CI p value Components Death Stroke Non Fatal MI New Renal Failure

21 Subgroups (1) 21

22 Subgroups (2) 22

23 Conclusions At 30 days there was no difference in the primary outcome between Off pump CABG and On pump CABG. Off-pump was associated with: Less transfusions and re-operation for bleeding Less acute kidney injury Less respiratory infections/failure More early revascularizations 23

24 Subgroups (2) 24

25 Results by Region EuroSCO RE OFF-PUMP ON-PUMP Hazard Ratio p value South America North America + Europe + Australia China India

26 Primary outcome per EuroSCORE 15 HR 1.35 HR 0.87 HR Primary Outcome () Off-pump On-pump Off-pump On-pump Off-pump On-pump to 5 >5 P=0.047 EuroSCORE

27 Primary Outcome per EuroSCORE 15 Primary Outcome () ON-PUMP to EuroSCORE 27

28 Primary Outcome per EuroSCORE 15 Primary Outcome () OFF-PUMP to EuroSCORE 28

29 Primary Outcome per EuroSCORE 15 Primary Outcome () OFF-PUMP ON-PUMP to EuroSCORE

30 Hazard Ratio 1.5 Hazard Ratio Off-pump/On-pump to EuroSCORE 30

31 Hazard Ratio 1.5 Hazard Ratio Off-pump/On-pump 1.0 ROOBY CORONARY GOPCAB E to EuroSCORE 31

32 Results by Region adjusted by EuroSCORE Eurosco re OFF-PUMP ON- PUMP HR 95 CI p value South America North America + Europe + Australia India China

33 Conclusions No variations of results per regions after adjustment by EuroSCORE Moderate and high risk patients tend to benefit from Off-pump technique compared to Onpump Reverse is seen in low-risk patients 33

34 1 st Co-Primary Outcome (1 Year) Primary Outcome Death, Stroke, MI, Renal Failure Components Off Pump On Pump Hazard Ratio 95 CI p value Death Stroke Non Fatal MI New Renal Failure

35 Other Outcomes at 1 Year Off Pump On Pump Hazard Ratio 95 CI p value Angina PCI Re-do CABG PCI/Re-do CABG Primary outcome per protocol

36 Death/MI/Stroke/New Renal Failure at 1 Year Primary Outcome () P=0.25 Months

37 Conclusions At 1 year there was no difference between Off-pump CABG and On-pump CABG: In the primary outcome Repeat revascularization Quality of life Neuro-cognitive function 37

38 38

39 39

40 1 st Co-Primary Outcome (30 Days) (830 patients) Primary Outcome Death, Stroke, MI, Renal Failure Components Off Pump On Pump Hazard Ratio 95 CI p value Death Stroke Non Fatal MI New Renal Failure * Not a pre-specified sub-group 40

41 1 st Co-Primary Outcome (Discharge) (830 patients) Primary Outcome Death, Stroke, MI, Renal Failure Components Off Pump On Pump Hazard Ratio 95 CI p value Death Stroke Non Fatal MI New Renal Failure

42 Other Outcomes at 30 days Off Pump On Pump Hazard Ratio 95 CI Blood transfusions AKI (stage 1) p value < < Re-hospitalization PCI Re-do CABG Re-operations All re-operations/re-do CABG/PCI

43 1 st Co-Primary Outcome (30 days to 1 Year) (830 Off Pump # pts patients) On Pump #pts Hazard Ratio 95 CI p value Primary Outcome Death, Stroke, MI, Renal Failure Components Death Stroke Non Fatal MI New Renal Failure PCI Re-do CABG

44 1 st Co-Primary Outcome (1 Year) (830 patients) Primary Outcome Death, Stroke, MI, Renal Failure Components Off Pump On Pump Hazard Ratio 95 CI p value Death Stroke Non Fatal MI New Renal Failure PCI Re-do CABG

45 Costs per patient at 1 year Off-pump $ On-pump $ Difference $ Initial Hospitalization Discharge to 6 months to 12 months Total The costs do not include the off-pump retractor or the CPB disposals The final cost will vary per center and their local contracts 45

46 Conclusions Significant benefits with Off-pump CABG at 30 days and 1 year in Canadian centres Same variation of risks/benefits by EuroSCORE is seen Reduction of $847 average cost per patient Off-pump CABG should be mastered by all Canadian cardiac surgeons 46

47 Recruitment CHUM: 309 Hamilton General: 210 London Univ. Hosp.: 106 Vancouver St Paul s: 61 Foothills Medical Centre: 51 Montreal Heart Institute: 35 Sunnybrook HSC: 30 Toronto General: 14 CHUS: 14 47

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year

CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study. Results at 1 Year CORONARY: The Coronary Artery Bypass Grafting Surgery Off or On Pump Revascularization Study Results at 1 Year André Lamy Population Health Research Institute Hamilton Health Sciences McMaster University

More information

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial

Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Randomized comparison of single versus double mammary coronary artery bypass grafting: 5 year outcomes of the Arterial Revascularization Trial Embargoed until 10:45 a.m. CT, Monday, Nov. 14, 2016 David

More information

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery

On-Pump vs. Off-Pump CABG: The Controversy Continues. Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-Pump vs. Off-Pump CABG: The Controversy Continues Miguel Sousa Uva Immediate Past President European Association for Cardiothoracic Surgery On-pump vs. Off-Pump CABG: The Controversy Continues Conflict

More information

Declaration of conflict of interest NONE

Declaration of conflict of interest NONE Declaration of conflict of interest NONE Claudio Muneretto MD, PhD Director of Division of Cardiac Surgery University of Brescia Medical School Italy Hybrid Chymera Different features and potential advantages

More information

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid?

Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid? Coronary Artery Bypass Grafting in Diabetics: All Arterial or Hybrid? Dr. Daniel Navia M.D. Chief Cardiac Surgery Department ICBA, Buenos Aires Argentina, 2018 No disclosures 2 Current evidence The FREEDOM

More information

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017

EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 EXCEL vs. NOBLE: How to Treat Left Main Disease in 2017 AATS International Cardiovascular Symposium December 8-9, 2017 Igor F. Palacios, MD Director of Interventional Cardiology Professor of Medicine Massachusetts

More information

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES

1. Whether the risks of stent thrombosis (ST) and major adverse cardiovascular and cerebrovascular events (MACCE) differ from BMS and DES 1 Comparison of Ischemic and Bleeding Events After Drug- Eluting Stents or Bare Metal Stents in Subjects Receiving Dual Antiplatelet Therapy: Results from the Randomized Dual Antiplatelet Therapy (DAPT)

More information

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb

Disclosures The PREVENT IV Trial was supported by Corgentech and Bristol-Myers Squibb Saphenous Vein Grafts with Multiple Versus Single Distal Targets in Patients Undergoing Coronary Artery Bypass Surgery: One-Year Graft Failure and Five-Year Outcomes from the Project of Ex-vivo Vein Graft

More information

Supplement materials:

Supplement materials: Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction

More information

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial)

Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Trial of Everolimus-Eluting Stents or Bypass Surgery for Coronary Disease (BEST Trial) Seung-Jung Park, MD, PhD On behalf of the BEST investigators Professor of Medicine, University of Ulsan College of

More information

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor

What oral antiplatelet therapy would you choose? a) ASA alone b) ASA + Clopidogrel c) ASA + Prasugrel d) ASA + Ticagrelor 76 year old female Prior Hypertension, Hyperlipidemia, Smoking On Hydrochlorothiazide, Atorvastatin New onset chest discomfort; 2 episodes in past 24 hours Heart rate 122/min; BP 170/92 mm Hg, Killip Class

More information

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017

GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY. Nick Collins February 2017 GRAND ROUNDS - DILEMMAS IN ANTICOAGULATION AND ANTIPLATELET THERAPY Nick Collins February 2017 DISCLOSURES Before I commence Acknowledge.. Interventional Cardiologist Perception evolved. Interventional

More information

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital

TRIAL UPDATE 1. ISAR TRIPLE SECURITY Trial. Dr Deven Patel Royal Free Hospital TRIAL UPDATE 1 ISAR TRIPLE SECURITY Trial Dr Deven Patel Royal Free Hospital NO CONFLICT OF INTEREST TO DECLARE ISAR TRIPLE Comparison of 6 weeks vs 6 months Triple Therapy in patients on oral anticoagulation

More information

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM

Version 4.4. Institutional Outcomes Report 2014Q3. National Outcomes Report Aggregation Date: Jan 12, :59:59 PM Version 4.4 Institutional Outcomes Report 2014Q3 National Outcomes Report 999997 Aggregation Date: Jan 12, 2015 11:59:59 PM Publish Date: Jan 29, 2015 If User desires to publish or otherwise distribute

More information

Use of Acute Kidney Injury Biomarkers in Clinical Trials

Use of Acute Kidney Injury Biomarkers in Clinical Trials Use of Acute Kidney Injury Biomarkers in Clinical Trials Design Considerations Amit X. Garg MD, MA (Education), FRCPC, PhD Nephrologist, London Health Sciences Centre Professor, Medicine and Epidemiology

More information

Use of Acute Kidney Injury Biomarkers in Clinical Trials

Use of Acute Kidney Injury Biomarkers in Clinical Trials Use of Acute Kidney Injury Biomarkers in Clinical Trials Design Considerations Amit X. Garg MD, MA (Education), FRCPC, PhD Nephrologist, London Health Sciences Centre Professor, Medicine and Epidemiology

More information

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France

Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Left Main Disease: what is left to surgery? Prof. Jacques Monségu CardioVascular Institute Grenoble, France Background on LM stenosis 5% of patients undergoing angiography Of the myocardium 80% Bifurcation

More information

Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days

Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days original article Off-Pump or On-Pump Coronary-Artery Bypass Grafting at 30 Days André Lamy, M.D., P.J. Devereaux, M.D., Ph.D., Dorairaj Prabhakaran, M.D., David P. Taggart, Ph.D., Shengshou Hu, M.D., Ernesto

More information

Emergency surgery in acute coronary syndrome

Emergency surgery in acute coronary syndrome Emergency surgery in acute coronary syndrome Teerawoot Jantarawan Division of Cardiothoracic Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand

More information

The MAIN-COMPARE Study

The MAIN-COMPARE Study Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial

Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and

More information

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study

Coronary Artery Stenosis. Insight from MAIN-COMPARE Study PCI for Unprotected Left Main Coronary Artery Stenosis Insight from MAIN-COMPARE Study Young-Hak Kim, MD, PhD Cardiac Center, University of Ulsan College of Medicine, Asan Medical Center Current Practice

More information

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators

STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY. Harvey D White on behalf of The STABILITY Investigators STABILITY Stabilization of Atherosclerotic plaque By Initiation of darapladib TherapY Harvey D White on behalf of The STABILITY Investigators Lipoprotein- associated Phospholipase A 2 (Lp-PLA 2 ) activity:

More information

EACTS Adult Cardiac Database

EACTS Adult Cardiac Database EACTS Adult Cardiac Database Quality Improvement Programme List of changes to Version 2.0, 13 th Dec 2018, compared to version 1.0, 1 st May 2014. INTRODUCTORY NOTES This document s purpose is to list

More information

Efficacy and Safety of a Dual Ticagrelor plus Aspirin Antiplatelet Strategy after Coronary Artery Bypass Grafting: The DACAB Randomized Clinical Trial

Efficacy and Safety of a Dual Ticagrelor plus Aspirin Antiplatelet Strategy after Coronary Artery Bypass Grafting: The DACAB Randomized Clinical Trial Efficacy and Safety of a Dual Ticagrelor plus Aspirin Antiplatelet Strategy after Coronary Artery Bypass Grafting: The DACAB Randomized Clinical Trial Qiang Zhao 1 Yunpeng Zhu 1, Zhiyun u 2, Zhaoyun Cheng

More information

SUPPLEMENTAL MATERIAL

SUPPLEMENTAL MATERIAL SUPPLEMENTAL MATERIAL Table S1: Number and percentage of patients by age category Distribution of age Age

More information

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction

Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Culprit PCI vs MultiVessel PCI for Acute Myocardial Infarction Dipti Itchhaporia, MD, FACC, FESC Trustee, American College of Cardiology Director of Disease Management, Hoag Hospital Robert and Georgia

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD for the CARES Investigators Calhoun Cardiology Center University

More information

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial

Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI. ISAR-REACT 4 Trial Abciximab plus Heparin versus Bivalirudin in Patients with NSTEMI Undergoing PCI ISAR-REACT 4 Trial Adnan Kastrati, MD Deutsches Herzzentrum, Technische Universität, Munich, Germany On behalf of F.-J.

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 89) is a regional and national referral center for percutaneous coronary intervention (PCI). A total of

More information

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators

Paris, August 28 th Gian Paolo Ussia on behalf of the CoreValve Italian Registry Investigators Paris, August 28 th 2011 Is TAVI the definitive treatment in high risk patients? Impact Of Coronary Artery Disease In Elderly Patients Undergoing TAVI: Insight The Italian CoreValve Registry Gian Paolo

More information

Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille

Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Lésions du tronc commun: Reste t il une place pour la chirugie? Pierre Deharo, CHU TIMONE, Marseille Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an

More information

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome

Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Surgical vs. Percutaneous Revascularization in Patients with Diabetes and Acute Coronary Syndrome Chris C. Cook, MD Associate Professor of Surgery Director, CT Residency Program, WVU ACOI 10/17/18 No Disclosures

More information

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria

ICSS Safety Results NOT for PUBLICATION. June 2009 ICSS ICSS ICSS ICSS. International Carotid Stenting Study: Main Inclusion Criteria Safety Results NOT for The following slides were presented to the Investigators Meeting on 22/05/09 and most of them were also presented at the European Stroke Conference on 27/05/09 They are NOT for in

More information

The Second Best Arterial Graft:

The Second Best Arterial Graft: The Second Best Arterial Graft: A Propensity Analysis of the Radial Artery Versus the Right Internal Thoracic Artery to Bypass the Circumflex Coronary Artery American Association for Thoracic Surgery,

More information

Incremental Value of Multiple Arterial conduits in CABG

Incremental Value of Multiple Arterial conduits in CABG Incremental Value of Multiple Arterial conduits in CABG Nirav C Patel MD FRCS CTh Professor Zucker School of Medicine at Hofstra Northwell Director of Robotic Cardiac Surgery Northwell Health Vice Chairman

More information

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease

Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Impact of Angiographic Complete Revascularization after Drug-Eluting Stent Implantation or Coronary Artery Bypass Surgery for Multivessel Coronary Disease Young-Hak Kim, Duk-Woo Park, Jong-Young Lee, Won-Jang

More information

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO!

Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Can Angiographic Complete Revascularization Improve Outcomes for Patients with Decreased LV Function? NO! Young-Hak Kim, MD, PhD Heart Institute, University of Ulsan College of Medicine Asan Medical Center,

More information

Supplement Table 1. Definitions for Causes of Death

Supplement Table 1. Definitions for Causes of Death Supplement Table 1. Definitions for Causes of Death 3. Cause of Death: To record the primary cause of death. Record only one answer. Classify cause of death as one of the following: 3.1 Cardiac: Death

More information

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy

Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Recognizing the High Risk NSTEMI Patient for Early Appropriate Therapy Learning Objectives Learn to recognize the high risk patient Discuss effective management of a high risk NSTEMI patient Review CCS

More information

SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS?

SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS? SURGICAL MYOCARDIAL REVASCULARIZATION: ARTERIAL VS VENOUS GRAFTS, SINGLE VS MULTIPLE GRAFTS? Luigi Martinelli Chief, Dept. of Surgery Istituto Clinico Ligure di Alta Specialità RAPALLO During 1987 2006,

More information

Supplementary Online Content

Supplementary Online Content Supplementary Online Content Inohara T, Manandhar P, Kosinski A, et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter

More information

'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome'

'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' 'Coronary artery bypass grafting in patients with acute coronary syndromes: perioperative strategies to improve outcome' Miguel Sousa Uva Chair ESC Cardiovascular Surgery WG Hospital da Cruz Vermelha Portuguesa

More information

Rationale for Prophylactic Support During Percutaneous Coronary Intervention

Rationale for Prophylactic Support During Percutaneous Coronary Intervention Rationale for Prophylactic Support During Percutaneous Coronary Intervention Navin K. Kapur, MD, FACC, FSCAI Assistant Director, Interventional Cardiology Director, Interventional Research Laboratories

More information

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial)

CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) CARDIOVASCULAR SAFETY OF FEBUXOSTAT OR ALLOPURINOL IN PATIENTS WITH GOUT AND CARDIOVASCULAR DISEASE (The CARES Trial) William B. White, MD, for the CARES Investigators Calhoun Cardiology Center University

More information

Adults With Diagnosed Diabetes

Adults With Diagnosed Diabetes Adults With Diagnosed Diabetes 1990 No data available Less than 4% 4%-6% Above 6% Mokdad AH, et al. Diabetes Care. 2000;23(9):1278-1283. Adults With Diagnosed Diabetes 2000 4%-6% Above 6% Mokdad AH, et

More information

PCI vs. CABG From BARI to Syntax, Is The Game Over?

PCI vs. CABG From BARI to Syntax, Is The Game Over? PCI vs. CABG From BARI to Syntax, Is The Game Over? Seung-Jung Park, MD, PhD Professor of Medicine, University of Ulsan College of Medicine Asan Medical Center, Seoul, Korea PCI vs CABG Multi-Vessel Disease

More information

Patient characteristics Intervention Comparison Length of followup

Patient characteristics Intervention Comparison Length of followup ISCHAEMIA TESTING CHAPTER TESTING FOR MYCOCARDIAL ISCHAEMIA VERSUS NOT TESTING FOR MYOCARDIAL ISCHAEMIA Ref ID: 4154 Reference Wienbergen H, Kai GA, Schiele R et al. Actual clinical practice exercise ing

More information

Ischemic Heart Disease Interventional Treatment

Ischemic Heart Disease Interventional Treatment Ischemic Heart Disease Interventional Treatment Cardiac Catheterization Laboratory Procedures (N = 11,61) is a regional and national referral center for percutaneous coronary intervention (PCI). A total

More information

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011

Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Implications of the New ESC/EACTS Guidelines for Myocardial Revascularization in 2011 Prof. Dr. Volkmar Falk Klinik für Herz- und Gefäßchirurgie, Universitätsspital Zürich, Schweiz In 2004 headlines were

More information

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events. ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.

More information

Catheter-based mitral valve repair MitraClip System

Catheter-based mitral valve repair MitraClip System Percutaneous Mitral Valve Repair: Results of the EVEREST II Trial William A. Gray MD Director of Endovascular Services Associate Professor of Clinical Medicine Columbia University Medical Center The Cardiovascular

More information

Current outcomes of off-pump coronary artery bypass grafting: evidence from real world practice

Current outcomes of off-pump coronary artery bypass grafting: evidence from real world practice Review Article Current outcomes of off-pump coronary artery bypass grafting: evidence from real world practice Piroze M. Davierwala Department of Cardiac Surgery, Heart Center, University of Leipzig, Leipzig,

More information

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD

HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD HIP ATTACK Trial: Can we improve outcomes after a hip fracture with accelerated surgery? PJ Devereaux, MD, PhD Disclosure Member of research group with policy of not accepting honorariums or other payments

More information

Transfusion triggers in acute coronary syndromes: The MINT trial

Transfusion triggers in acute coronary syndromes: The MINT trial Transfusion triggers in acute coronary syndromes: The MINT trial Paul Hébert, MD MHSc(Epid) Physician-in-Chief, CHUM Professor, University of Montreal Objectives Review evidence on transfusion triggers

More information

Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009

Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009 Western University Scholarship@Western Electronic Thesis and Dissertation Repository June 2015 Secular Trends in Cardiovascular Disease in Kidney Transplant Recipients: 1994 to 2009 Ngan Lam The University

More information

Unprotected LM intervention

Unprotected LM intervention Unprotected LM intervention Guideline for COMBAT Seung-Jung Park, MD, PhD Professor of Internal Medicine, Seoul, Korea Current Recommendation for unprotected LMCA Stenosis Class IIb C in ESC guideline

More information

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome

PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome CEDAC FINAL RECOMMENDATION PRASUGREL HYDROCHLORIDE (Effient Eli Lilly Canada Inc.) Indication: Acute Coronary Syndrome Recommendation: The Canadian Expert Drug Advisory Committee (CEDAC) recommends that

More information

Management of High-Risk CAD : Surgeons Perspective

Management of High-Risk CAD : Surgeons Perspective Management of High-Risk CAD : Surgeons Perspective Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Conflict : Cardiac Surgeon! High Risk CABG 77 year old with prior large anterior

More information

LOW RISK TAVR. WHAT THE FUTURE HOLDS

LOW RISK TAVR. WHAT THE FUTURE HOLDS LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular

More information

Management of cardiovascular disease - coronary interventions -

Management of cardiovascular disease - coronary interventions - Master Classes in Preventive Cardiology I Management of diabetes in patients with CVD European Heart House Management of cardiovascular disease - coronary interventions - Francesco Cosentino MD, PhD, FESC

More information

Robotic Hybrid Coronary Revascularization

Robotic Hybrid Coronary Revascularization Robotic Hybrid Coronary Revascularization Important benefits before, during, and after surgery If you have coronary artery disease (CAD), your doctor may discuss several treatment options with you. These

More information

Diagnostic, Technical and Medical

Diagnostic, Technical and Medical Diagnostic, Technical and Medical Approaches to Reduce CABG Related Stroke Pieter Kappetein, Michael Mack, M.D. Dept Thoracic Surgery, Rotterdam, The Netherlands Baylor Healthcare System Dallas, TX Background

More information

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG

OPCAB IS NOT BETTER THAN CONVENTIONAL CABG OPCAB IS NOT BETTER THAN CONVENTIONAL CABG Harold L. Lazar, M.D. Harold L. Lazar, M.D. Professor of Cardiothoracic Surgery Boston Medical Center and the Boston University School of Medicine Boston, MA

More information

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL

TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL TICAGRELOR VERSUS CLOPIDOGREL AFTER THROMBOLYTIC THERAPY IN PATIENTS WITH ST- ELEVATION MYOCARDIAL INFARCTION: A RANDOMIZED CLINICAL TRIAL Otavio Berwanger, MD, PhD - On behalf of the TREAT Trial Steering

More information

PTCA 1979: : I

PTCA 1979: : I The SYNTAX Message is Clear: CABG is Preferred in Complex MVD Angioplasty Summit TCTAP 2012 Seoul, Korea April 2012 David R. Holmes, MD Mayo Clinic Rochester, MN Presenter Disclosure Information David

More information

Is there enough evidence for DAPT after endovascular intervention for PAOD?

Is there enough evidence for DAPT after endovascular intervention for PAOD? Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...

More information

INDIVIDUALIZED MEDICINE

INDIVIDUALIZED MEDICINE CENTER FOR INDIVIDUALIZED MEDICINE Clopidogrel Pharmacogenetics Can We Impact Clinical Practice? Michael E. Farkouh, MD, MSc Peter Munk Cardiac Centre University of Toronto Naveen Pereira MD Mayo Clinic

More information

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium

FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium FFR and CABG Emanuele Barbato, MD, PhD, FESC Cardiovascular Center Aalst, Belgium Conflict of Interest Institutional research grants and speaker s fee from St. Jude Medical and Boston Scientic to Cardiovascular

More information

The top 5 trials in the last year: Ischemic Heart Disease

The top 5 trials in the last year: Ischemic Heart Disease The top 5 trials in the last year: Ischemic Heart Disease Malcolm R. Bell, MBBS, FRACP, FACC Vice Chair, Department of Cardiovascular Medicine Mayo Clinic, Rochester MN, USA 2018 MFMER 3718476-1 Conflicts

More information

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea

Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm

More information

AF stroke prevention in the Canadian context

AF stroke prevention in the Canadian context AF stroke prevention in the Canadian context 5 th Annual State of the Heart Toronto, May 31, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology Toronto General Hospital, University Health Network

More information

The ACCELERATE Trial

The ACCELERATE Trial The ACCELERATE Trial Impact of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib on Cardiovascular Outcome Stephen J Nicholls for the ACCELERATE investigators Disclosure Research support: AstraZeneca,

More information

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES

UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES UPDATES FROM THE 2018 ANTIPLATELET GUIDELINES Claudia Bucci BScPhm, PharmD Clinical Coordinator, Cardiovascular Diseases Sunnybrook Health Sciences Centre 21st Annual Contemporary Therapeutic Issues in

More information

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None

8/28/2018. Pre-op Evaluation for non cardiac surgery. A quick review from 2007!! Disclosures. John Steuter, MD. None Pre-op Evaluation for non cardiac surgery John Steuter, MD Disclosures None A quick review from 2007!! Fliesheret al, ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and are for Noncardiac

More information

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS

A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS A Randomized Trial Evaluating Clinically Significant Bleeding with Low-Dose Rivaroxaban vs Aspirin, in Addition to P2Y12 inhibition, in ACS Magnus Ohman MB, on behalf of the GEMINI-ACS-1 Investigators

More information

Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?

Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery? Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery? Damien J. LaPar MD, MSc, James M. Isbell MD, MSCI, Jeffrey B. Rich MD, Alan M. Speir MD, Mohammed

More information

Alfa Ferry FRCS Cardiac Surgeon OPERATIVE MANAGEMENT IN CORONARY ARTERY DISEASE

Alfa Ferry FRCS Cardiac Surgeon OPERATIVE MANAGEMENT IN CORONARY ARTERY DISEASE Alfa Ferry FRCS Cardiac Surgeon OPERATIVE MANAGEMENT IN CORONARY ARTERY DISEASE Management in CHD Medical (medikamentosa) Intervensi 1. Percutaneous ( PTCA & stenting ) 2. Surgical ( CABG, CABG & mitral

More information

Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation

Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation Minimally Invasive Stand Alone Cox-Maze Procedure For Patients With Non-Paroxysmal Atrial Fibrillation Niv Ad, MD Chief, Cardiac Surgery Inova Heart and Vascular Institute Disclosures Niv Ad: Medtronic

More information

Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis

Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis Does the Use of Ultrafiltration Increase the Risk of Post-Operative Acute Kidney Injury? A Multi-Center Analysis Gordon R. DeFoe, CCP, John Pieroni, CCP, Craig S. Warren, CCP, Charles F. Krumholz, CCP,

More information

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Vladimir Ganyukov, MD, PhD

HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease. Vladimir Ganyukov, MD, PhD HREVS: A Randomized Trial of PCI vs CABG vs Hybrid Revascularization in Patients With Coronary Artery Disease Vladimir Ganyukov, MD, PhD Nikita Kochergin MD, Aleksandr Shilov MD, PhD, Roman Tarasov, MD,

More information

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY

COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY COAGULATION, BLEEDING, AND TRANSFUSION IN URGENT AND EMERGENCY CORONARY SURGERY VALTER CASATI, M.D. DIVISION OF CARDIOVASCULAR ANESTHESIA AND INTENSIVE CARE CLINICA S. GAUDENZIO NOVARA (ITALY) ANTIPLATELET

More information

Coronary Revascularization Rates in Ontario: Which rate is right?

Coronary Revascularization Rates in Ontario: Which rate is right? Coronary Revascularization Rates in Ontario: Which rate is right? Jack V. Tu,, MD PhD FRCPC Division of General Internal Medicine, Sunnybrook & Women s College Health Science Centre University of Toronto

More information

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital

VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital VCU Pauley Heart Center: A 2009 US News Top 50 Heart and Heart Surgery Hospital Complex PCI: Multivessel Disease George W. Vetrovec, MD. Kimmerling Chair of Cardiology VCU Pauley Heart Center Virginia

More information

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai.

Disclosures. Dr. Scirica has also served as a consultant for Lexicon, Arena, Gilead, and Eisai. Disclosures Benjamin M. Scirica, MD, MPH, is employed by the TIMI Study Group, which has received research grants from Abbott, AstraZeneca, Amgen, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb,

More information

Count Down to COMBAT

Count Down to COMBAT Count Down to COMBAT Randomized COMparison of Bypass Surgery versus AngioplasTy using Sirolimus-Eluting Stent in Patients with Left Main Coronary Artery Disease Roxana Mehran, MD Associate Professor of

More information

Zachary I. Hodes, M.D., Ph.D., F.A.C.C.

Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Zachary I. Hodes, M.D., Ph.D., F.A.C.C. Disclamer: I personally have no financial relationship with any company mentioned today. The Care Group, LLC does have a contract with Cardium to participate in

More information

The MAIN-COMPARE Registry

The MAIN-COMPARE Registry Long-Term Outcomes of Coronary Stent Implantation versus Bypass Surgery for the Treatment of Unprotected Left Main Coronary Artery Disease Revascularization for Unprotected Left MAIN Coronary Artery Stenosis:

More information

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials

Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La

More information

Which drug do you prefer for stable CAD? - P2Y12 inhibitor

Which drug do you prefer for stable CAD? - P2Y12 inhibitor Which drug do you prefer for stable CAD? - P2Y12 inhibitor Jung Rae Cho, MD, PhD Cardiovascular Division, Department of Internal Medicine Kangnam Sacred Heart Hospital, Hallym University Medical Center,

More information

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology

STEMI update. Vijay Krishnamoorthy M.D. Interventional Cardiology STEMI update Vijay Krishnamoorthy M.D. Interventional Cardiology OVERVIEW Current Standard of Care in Management of STEMI Update in management of STEMI Pre-Cath Lab In the ED/Office/EMS. Cath Lab Post

More information

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands

DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS. Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands DOUBLE or TRIPLE ANTI-TROMBOTIC THERAPY in ACS Maarten L Simoons Thoraxcenter - Erasmus MC Rotterdam - The Netherlands RECENT DEVELOPMENTS Better anti-platelet agents: Prasugrel and Ticagrelor to replace

More information

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals.

OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME. TARGET AUDIENCE: All Canadian health care professionals. OUTPATIENT ANTITHROMBOTIC MANAGEMENT POST NON-ST ELEVATION ACUTE CORONARY SYNDROME TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To review the use of antiplatelet agents and oral

More information

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD

Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Safety of Single- Versus Multi-vessel Angioplasty for Patients with AMI and Multi-vessel CAD Mun K. Hong, MD Associate Professor of Medicine Director, Cardiovascular Intervention and Research Weill Cornell

More information

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION

STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION STATINS EVALUATION IN CORONARY PROCEDURES AND REVASCULARIZATION Otávio Berwanger, MD, FACS - On behalf of the SECURE Steering Committee and Investigators Trial Organization Trial Steering Committee Dr.

More information

An introduction to Quality by Design. Dr Martin Landray University of Oxford

An introduction to Quality by Design. Dr Martin Landray University of Oxford An introduction to Quality by Design Dr Martin Landray University of Oxford Criteria for a good trial Ask an IMPORTANT question Answer it RELIABLY Quality Quality is the absence of errors that matter to

More information

CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW

CORONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP OVERVIEW 2015 PQRS OPTIONS F MEASURES GROUPS: 2015 PQRS MEASURES IN CONARY ARTERY BYPASS GRAFT (CABG) MEASURES GROUP: #43 Coronary Artery Bypass Graft (CABG):

More information

CPORT E Trial. Atlantic C PORT

CPORT E Trial. Atlantic C PORT CPORT E Trial Randomized trial comparing medical, economic and quality of life outcomes of non primary PCI at hospitals with and without on site cardiac surgery Mo#va#on for Trial Sustain primary PCI program

More information

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.

Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν. Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,

More information

ANZSCTS Cardiac Surgery Database Program ANNUAL REPORT ANZSCTS National Report 2015 Page 1

ANZSCTS Cardiac Surgery Database Program ANNUAL REPORT ANZSCTS National Report 2015 Page 1 ANZSCTS Cardiac Surgery Database Program ANNUAL REPORT 2015 ANZSCTS National Report 2015 Page 1 The Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) Cardiac Surgery Database

More information